An experienced CEO with a background building entrepreneurial organizations including fundraising, strategy development, licensing, and M&A in Asia, Europe and the United States. Previously, he was CEO of Sirus Limited, a drug targeting and delivery company and Lotus Healthcare Corporation, a fully integrated pharma company in Asia. He has an MBA from Harvard and doctoral studies at Max Planck Institute. Tom is a board member of EuropaBio.

Sarah has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas. She was VP for CMC (Chemistry, Manufacturing and Controls) of BTG plc. and Director of Outsourced Manufacturing at UCB. She started her career in API process development at Glaxo Smith Kline. She holds a PhD in Physical Organic Chemistry from St Andrews.

Jan, the principal inventor of the core protein stabilisation technologies, is a biochemist with a strong background in physical chemistry. Previously he was a Principal Scientist at Insense Limited. Holds a joint Doctorate from the Bedfordshire and the University of Chemical Technology, Prague. He is a member of the Scientific Advisory Board of the Centre of Excellence in Biopharmaceuticals (University of Manchester).

Stephen had 10 years experience in scientific roles with GSK prior to undertaking an MBA at the University of Cambridge. He brings a solid understanding of the science and needs of major pharmaceutical companies to building the commercial relationships for Arecor. In addition to his MBA Stephen holds a PhD in Molecular Cell Biology from the University of Dundee.